Overcoming Lymphoma with Dual CAR-T Therapy

A 61-year-old woman, who had endured multiple treatments for diffuse large B-Cell Lymphoma, including seven chemotherapy cycles, CAR-T therapy, and numerous rounds of PD-1 combined chemotherapy and radiation, found herself at a crossroads. Despite her efforts, her condition showed little improvement until she arrived at BIOOCUS for specialized care.

In early 2021, with her lymphoma rapidly progressing and causing severe skin ulcers and swelling, the patient's situation appeared dire. Under the care of the dedicated team at BIOOCUS, she began a new treatment journey. After initial treatments, her condition stabilized, leading to the collection and cultivation of her lymphocytes for CD19/CD22 CAR-T cell therapy.

On February 19, 2021, she received the dual CAR-T cell infusion. Though she experienced manageable side effects, subsequent PET-CT scans revealed significant improvement. By March, she achieved near-complete remission, marking a turning point in her battle against cancer.

Now, three years post-CAR-T therapy, she actively shares her recovery story at the Fourth China Lymphoma Patient Conference, inspiring others facing similar challenges. Her journey underscores the advancements in CAR-T therapies and the crucial role of personalized medicine in treating complex lymphomas.

Thanks to the comprehensive care at BIOOCUS, she continues to thrive, emphasizing the importance of innovative treatments and the support of dedicated healthcare professionals in overcoming cancer.